The interleukin-27 receptor is a type I cytokine receptor for interleukin-27. It is a heterodimer composed of the interleukin 27 receptor, alpha subunit[1][2] and glycoprotein 130.[3]
IL27RA essential for transcriptional activation of STAT1 and for augmenting the induction of T-bet expression during initiation of Th1 cell differentiation.[4]
References
- ^ Sprecher CA, Grant FJ, Baumgartner JW, Presnell SR, Schrader SK, Yamagiwa T, Whitmore TE, O'Hara PJ, Foster DF (1998). "Cloning and characterization of a novel class I cytokine receptor". Biochem. Biophys. Res. Commun. 246 (1): 82–90. doi:10.1006/bbrc.1998.8576. PMID 9600072.
- ^ Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, Gurney A, Grewal IS, de Sauvage FJ (2000). "Development of Th1-type immune responses requires the type I cytokine receptor TCCR". Nature. 407 (6806): 916–20. Bibcode:2000Natur.407..916C. doi:10.1038/35038103. PMID 11057672. S2CID 205009928.
- ^ Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal Malefyt R, Kastelein RA (February 2004). "WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27". Journal of Immunology. 172 (4): 2225–31. doi:10.4049/jimmunol.172.4.2225. PMID 14764690.
- ^ Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H (May 2003). "Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment". J. Immunol. 170 (10): 4886–90. doi:10.4049/jimmunol.170.10.4886. PMID 12734330.
External links
|
|---|
| IL-1 |
- Antagonists: AF-12198
- Anakinra
- IL-1RA
- Isunakinra
- Antibodies: Canakinumab
- Gevokizumab
- Lutikizumab
- Decoy receptors: Rilonacept (IL-1 Trap)
|
|---|
| IL-2 |
- Agonists: Adargileukin alfa
- Aldesleukin
- Celmoleukin
- Denileukin diftitox
- Interleukin 2
- Pegaldesleukin
- Teceleukin
- Tucotuzumab celmoleukin
- Antibodies: Basiliximab
- Daclizumab (dacliximab)
- Inolimomab
|
|---|
| IL-3 | |
|---|
| IL-4 |
- Antibodies: Dupilumab
- Pascolizumab
|
|---|
| IL-5 |
- Antibodies: Benralizumab
- Mepolizumab
- Reslizumab
- Antisense oligonucleotides: TPI ASM8
|
|---|
| IL-6 |
- Antibodies: ARGX-109
- Clazakizumab
- Elsilimomab
- mAb 1339
- Olokizumab
- Sarilumab
- Siltuximab
- Sirukumab
- Tocilizumab
- Levilimab
|
|---|
| IL-7 | |
|---|
| IL-8 |
- See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.
|
|---|
| IL-9 | |
|---|
| IL-10 | |
|---|
| IL-11 | |
|---|
| IL-12 |
- Antibodies: Briakinumab
- Ustekinumab
|
|---|
| IL-13 |
- Antibodies: Anrukinzumab
- Lebrikizumab
- Tralokinumab
|
|---|
| IL-15 | |
|---|
| IL-17 |
- Antibodies: Brodalumab
- Ixekizumab
- Perakizumab
- Remtolumab
- Secukinumab
- Vunakizumab
|
|---|
| IL-18 | |
|---|
| IL-20 |
- Antibodies: Fletikumab (against IL-20)
|
|---|
| IL-21 |
- Antibodies: NNC0114-0005
- NNC0114-0006
|
|---|
| IL-22 |
- Antibodies: Fezakinumab (against IL-22)
|
|---|
| IL-23 |
- Agonists: Interleukin 23 (SGRF)
- Antibodies: Brazikumab
- Briakinumab
- Guselkumab
- Risankizumab
- Tildrakizumab
- Ustekinumab
|
|---|
| |
|---|
| IL-28 | |
|---|
| IL-31 | |
|---|
| IL1RL1 | |
|---|
| IL1RL2 | |
|---|
| Others | | JAK | |
|---|
| Others |
- Unsorted: Efavaleukin alfa
- Efineptakin alfa
|
|---|
|
|---|